Guarding Life, Inspiring a Healthier World

The company is committed to its mission of “Guarding Life, Inspiring a Healthier World.”

It focuses on the research, development, manufacturing, and commercialization of interventional devices for structural heart disease, and operates several subsidiaries, including Hongyu Medical, Hanyu Singapore, and Hanyu Guangdong.

In the field of structural heart disease intervention, the company’s innovative medical device — the ValveClamp® Mitral Valve Repair System — received official approval from the National Medical Products Administration (NMPA) in September 2023, becoming the first domestically approved transcatheter mitral regurgitation repair device in China.

As of 2025, the product has entered commercial sales in Indonesia, Thailand, Singapore, Vietnam, and Colombia.

The company’s R&D pipeline covers a broad range of interventional therapies for structural heart diseases.

Among them, the ReAces® Atrial Septal Defect Occluder has completed patient enrollment in its registration clinical trial and entered the follow-up stage, while the ValveClasp® Transcatheter Mitral Valve Repair System was included in China’s Special Review Procedure for Innovative Medical Devices in 2023 and is currently undergoing clinical evaluation.

The company’s products have been applied in over 60 hospitals across China and are being commercialized in more than 20 countries worldwide, accelerating the global presence of China’s innovative medical technologies.

Hanyu Medical has been deeply engaged in the field of structural heart disease, committed to providing safe, effective, and accessible integrated solutions to address significant unmet clinical needs in China and around the world, thereby improving patients’ survival and quality of life.

Looking ahead, Hanyu Medical will continue to focus on addressing unmet clinical needs in structural heart disease through continuous technological innovation and global commercialization, driving the advancement of China’s high-end medical device industry and contributing to better patient outcomes and longer lives.